Treatments with GSK-J4 were found to be associated with the induction of apoptosis and increased expression of pro-inflammatory cytokines. As such our results demonstrate that whilst members of the Kdm6 family are overexpressed in MPM they may not be suitable candidates for therapy and may elicit a cytokine storm.
February 19, 2017
, Biphasic or Mixed
, Cisplatin (Platinol ®)
, Full Archive
, Gene Therapy
, New & Novel
, Pemetrexed (Alimta)
, Raltitrexed (Tomudex)
Comments Off on Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma
CONCLUSION: The omission of the elective irradiation of the whole ipsilateral pleural space allowed dose escalation from 49 Gy to more than 58 Gy in 4 of 12 chemonaive MPM patients. This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.
February 18, 2017
Comments Off on Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study
He was treated with pleuropneumonectomy, radiotherapy, and adjuvant chemotherapy. Although the best treatment for this rare condition has not been defined, we thought that tumor resection and adjuvant therapy were appropriate to control the disease in this case.
February 17, 2017
Comments Off on Large primary pleural synovial sarcoma with severe dyspnea: a case report
Moreover, EP reduced HMGB1 serum levels in mice and inhibited the growth of MM xenografts. Our results indicate that EP effectively hampers the malignant phenotype of MM, offering a novel potential therapeutic approach to patients afflicted with this dismal disease.
February 17, 2017
Comments Off on HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma
With a relatively large database of 17 phase II trials and 716 patients from Cancer and Leukemia Group B and North Central Cancer Treatment Group, we conducted statistical analyses and found that there is no evidence to suggest that PFS is a valid surrogate endpoint for OS for malignant mesothelioma. Future research work is needed to find alternative surrogate endpoints for OS.
February 16, 2017
Comments Off on Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
3±0. 1 (SE) in 171 controls (p.
February 15, 2017
Comments Off on 3-(2-deoxy-β-D-erythro-pentafuranosyl)pyrimido[1,2-α]purin-10(3H)-one deoxyguanosine adducts of workers exposed to asbestos fibers
CONCLUSIONS: Long-term regional chemotherapy was associated with improved survival in patients with MPM. In this rare disease, additional phase 2 investigations are suggested.
February 14, 2017
Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival
Notably, a TG2-selective irreversible inhibitor that reacts with the intracellular active form of TG2, but not a non-cell-permeable inhibitor, significantly compromised cell viability in MPM spheroids. Understanding the expression and function of TG2 in the adaptation to the hypoxic environment may provide useful information for novel promising therapeutic options for MPM treatment.
February 12, 2017
Comments Off on Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia
CONCLUSIONS: From the available literature no serum or pleural fluid biomarker was identified that could be recommended currently for routine clinical practice. However, a falling serum soluble mesothelin might correlate with treatment response and improved survival.
February 11, 2017
Comments Off on Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation. Therefore, PDPN might be a pathogenetic determinant of MPM dissemination and aggressive growth and may thus be an ideal therapeutic target.
February 10, 2017
Comments Off on Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation